SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 26 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1809 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS